Renaissance Technologies (RenTech)'s LGND Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 7,094 shares of Ligand Pharmaceuticals Incorporated (LGND) worth $2.22 M, representing 0.00% of the portfolio. First purchased in 2014-Q2, this long-term strategic position has been held for 35 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in LGND, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2018, adding 726,600 shares. Largest reduction occurred in Q2 2020, reducing 464,400 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Ligand Pharmaceuticals Incorporated (LGND) Holding Value Over Time
Track share changes against reported price movement
Quarterly Ligand Pharmaceuticals Incorporated (LGND) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2026 | +7,094 | New Buy | 7,094 | $312.37 |
| Q4 2024 | -3,000 | Sold Out | 0 | $0.00 |
| Q3 2024 | -15,200 | Reduce 83.52% | 3,000 | $100.09 |
| Q2 2024 | -28,900 | Reduce 61.36% | 18,200 | $84.26 |
| Q1 2024 | -19,200 | Reduce 28.96% | 47,100 | $73.10 |
| Q4 2023 | +10,600 | Add 19.03% | 66,300 | $71.42 |
| Q3 2023 | +13,300 | Add 31.37% | 55,700 | $59.93 |
| Q2 2023 | +12,600 | Add 42.28% | 42,400 | $0.07 |
| Q1 2023 | +5,300 | Add 21.63% | 29,800 | $0.07 |
| Q4 2022 | +7,800 | Add 46.71% | 24,500 | $0.07 |
| Q3 2022 | -1,294 | Reduce 7.19% | 16,700 | $86.11 |
| Q2 2022 | +17,994 | New Buy | 17,994 | $89.20 |
| Q3 2020 | -135,544 | Sold Out | 0 | $0.00 |
| Q2 2020 | -464,400 | Reduce 77.41% | 135,544 | $111.85 |
| Q1 2020 | -421,245 | Reduce 41.25% | 599,944 | $72.72 |
| Q4 2019 | -198,225 | Reduce 16.26% | 1.02 M | $104.29 |
| Q3 2019 | -61,394 | Reduce 4.79% | 1.22 M | $99.54 |
| Q2 2019 | -134,900 | Reduce 9.53% | 1.28 M | $114.15 |
| Q1 2019 | -65,111 | Reduce 4.40% | 1.42 M | $125.71 |
| Q4 2018 | +726,600 | Add 96.34% | 1.48 M | $135.70 |
| Q3 2018 | +230,725 | Add 44.07% | 754,219 | $274.49 |
| Q2 2018 | +159,100 | Add 43.66% | 523,494 | $207.17 |
| Q1 2018 | +314,994 | Add 637.64% | 364,394 | $165.16 |
| Q4 2017 | +49,400 | New Buy | 49,400 | $136.92 |
| Q3 2017 | -78,094 | Sold Out | 0 | $0.00 |
| Q2 2017 | -23,021 | Reduce 22.77% | 78,094 | $121.40 |
| Q1 2017 | +101,115 | New Buy | 101,115 | $105.84 |
| Q3 2016 | -116,004 | Sold Out | 0 | $0.00 |
| Q2 2016 | -796 | Reduce 0.68% | 116,004 | $119.27 |
| Q1 2016 | -57,500 | Reduce 32.99% | 116,800 | $107.09 |
| Q4 2015 | +102,100 | Add 141.41% | 174,300 | $108.42 |
| Q3 2015 | -23,894 | Reduce 24.87% | 72,200 | $85.65 |
| Q2 2015 | +96,094 | New Buy | 96,094 | $100.90 |
| Q3 2014 | -38,594 | Sold Out | 0 | $0.00 |
| Q2 2014 | +38,594 | New Buy | 38,594 | $62.29 |
Renaissance Technologies (RenTech)'s Ligand Pharmaceuticals Incorporated Investment FAQs
Renaissance Technologies (RenTech) first purchased Ligand Pharmaceuticals Incorporated (LGND) in Q2 2014, acquiring 38,594 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Ligand Pharmaceuticals Incorporated (LGND) for 35 quarters since Q2 2014.
Renaissance Technologies (RenTech)'s largest addition to Ligand Pharmaceuticals Incorporated (LGND) was in Q4 2018, adding 1,480,819 shares worth $200.95 M.
According to the latest 13F filing for Q3 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 7,094 shares of Ligand Pharmaceuticals Incorporated (LGND), valued at approximately $2.22 M.
As of the Q3 2026 filing, Ligand Pharmaceuticals Incorporated (LGND) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Ligand Pharmaceuticals Incorporated (LGND) was 1,480,819 shares, as reported at the end of Q4 2018.